Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway. Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.